Cite
HARVARD Citation
Banna, G. et al. (2022). Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy. Thoracic cancer. 13 (3), pp. 483-488. [Online].